Chronic Obstructive Pulmonary Disease Pipeline Summary

DelveInsight’s, “Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 77+ pipeline drugs in Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Obstructive Pulmonary Disease: Understanding

Chronic Obstructive Pulmonary Disease: Overview

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases. Predominantly, COPD includes emphysema and chronic bronchitis.

COPD results from lifelong interactions between genetic susceptibility and environmental exposures. Cigarette smoking is the leading cause, accounting for most cases in high-income countries, while biomass fuel smoke, occupational exposure to dusts, chemicals, and fumes, and air pollution are important contributors worldwide. Additional risk factors include recurrent childhood respiratory infections, previous pulmonary tuberculosis, abnormal lung development, asthma with persistent airflow limitation, accelerated lung aging, and the inherited disorder ?1-antitrypsin deficiency, which predisposes individuals to early-onset emphysema through an imbalance between proteases and antiproteases.

OPD is driven by an exaggerated inflammatory response to inhaled noxious particles in genetically susceptible individuals. Chronic exposure to cigarette smoke or other irritants activates neutrophils, macrophages, CD8? T lymphocytes, and other inflammatory cells, leading to the release of proteases, reactive oxygen species, and pro-inflammatory cytokines that damage lung tissue. In emphysema, protease-antiprotease imbalance causes irreversible destruction of alveolar walls, reducing elastic recoil and resulting in air trapping and hyperinflation. Concurrently, small airway disease is characterized by inflammation, fibrosis, goblet cell hyperplasia, mucus hypersecretion, airway wall thickening, and mucus plugging, producing fixed airflow limitation.

The diagnosis of COPD is based on a combination of clinical assessment and objective pulmonary function testing. COPD should be suspected in individuals over 40 years of age with chronic respiratory symptoms and significant exposure to risk factors. Post-bronchodilator spirometry is the gold standard for diagnosis, with a forced expiratory volume in one second (FEV?)/forced vital capacity (FVC) ratio below 0.70 confirming persistent airflow obstruction. Disease severity is further evaluated using FEV? percentage predicted, symptom assessment tools such as the Modified Medical Research Council (mMRC) Dyspnea Scale and COPD Assessment Test (CAT), exacerbation history, and blood eosinophil counts.

The goal of treating COPD impairment is to minimize the impact of the current impairment and prevent the development of further impairment. Depending on the severity, the deterioration can be treated on an outpatient or hospital basis. Most of the time, outpatient treatment is sufficient to use medications, including bronchodilators, corticosteroids, and antibiotics. Nonpharmacological interventions include ventilatory support and chest physical therapy.

"Chronic Obstructive Pulmonary Disease- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Obstructive Pulmonary Disease pipeline landscape is provided which includes the disease overview and Chronic Obstructive Pulmonary Disease treatment guidelines. The assessment part of the report embraces, in depth Chronic Obstructive Pulmonary Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Obstructive Pulmonary Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters

This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Obstructive Pulmonary Disease Emerging Drugs

• Tezepelumab: Amgen/AstraZeneca

TEZSPIRE (tezepelumab?ekko) is a human monoclonal antibody administered by subcutaneous injection. It blocks the action of thymic stromal lymphopoietin (TSLP), an epithelial cytokine that operates near the top of multiple inflammatory pathways. Because TSLP is released by airway epithelial cells in response to triggers like allergens, pollutants, viruses, or smoke, and because it helps to initiate downstream immune responses, inhibiting TSLP has the potential to suppress a broad range of airway inflammation. TEZSPIRE is jointly developed by Amgen and AstraZeneca. The drug is currently in Phase III stage of its development for the treatment of Chronic Obstructive Pulmonary Disease.

• AZD6793: AstraZeneca

AZD6793 is an investigational inhaled antisense oligonucleotide (ASO) designed to selectively reduce the expression of a disease-associated target implicated in airway inflammation through an RNA-targeting approach. As an antisense oligonucleotide, AZD6793 binds to its complementary messenger RNA (mRNA), promoting its degradation or preventing its translation, thereby lowering production of the target protein. By suppressing this target locally within the lungs via inhalation, AZD6793 is intended to reduce chronic airway inflammation and its downstream pathological effects while minimizing systemic exposure. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Obstructive Pulmonary Disease.

• BBT002: Bambusa Therapeutics

BBT002 is an investigational half-life extended bispecific monoclonal antibody designed as a “platform-in-a-molecule” that simultaneously targets interleukin-4 receptor alpha (IL-4R?) and interleukin-5 (IL-5), thereby inhibiting the IL-4, IL-13, and IL-5 signaling pathways that drive type 2 inflammation. Through dual blockade of these non-redundant pathways, BBT002 aims to reduce Th2-mediated inflammation, eosinophilic activity, mucus hypersecretion, tissue remodeling, and airway damage while preventing inflammatory pathway escape that can occur with single-target therapies. The antibody also incorporates Fc modifications that eliminate unwanted effector functions and extend serum half-life, enabling longer dosing intervals. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Chronic Obstructive Pulmonary Disease.

• SPL5AC: SpliSense

SPL5AC is an investigational inhaled antisense oligonucleotide (ASO) being developed by SpliSense for the treatment of muco-obstructive pulmonary diseases, including chronic obstructive pulmonary disease (COPD). The therapy is designed to target MUC5AC, a gel-forming mucin that is overexpressed in COPD and contributes to excessive, highly viscous mucus accumulation, airway obstruction, chronic infection, and inflammation. Its mechanism of action involves binding specifically to MUC5AC mRNA, thereby reducing MUC5AC gene expression and subsequent mucin production. By lowering MUC5AC levels, SPL5AC aims to decrease mucus viscosity, promote mucus clearance, reduce airway plugging, and mitigate infection and inflammation. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Chronic Obstructive Pulmonary Disease.

Further product details are provided in the report……..

Chronic Obstructive Pulmonary Disease: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic Obstructive Pulmonary Disease

There are approx. 75+ key companies which are developing the therapies Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. Phase III include Amgen and Astrazeneca and others.

• Phases

DelveInsight’s report covers around 77+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Obstructive Pulmonary Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Obstructive Pulmonary Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Obstructive Pulmonary Disease drugs.

Chronic Obstructive Pulmonary Disease Report Insights

• Chronic Obstructive Pulmonary Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Obstructive Pulmonary Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Obstructive Pulmonary Disease drugs?
• How many Chronic Obstructive Pulmonary Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Obstructive Pulmonary Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Obstructive Pulmonary Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Obstructive Pulmonary Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Amgen
• AstraZeneca
• GSK
• Uniquity Bio
• Bambus Therapeutics
• SpliSense
• Hengrui Pharmaceutical
• Haisco Pharmaceutical Group Co., Ltd.
• Hoffmann-La Roche
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Keymed Biosciences Co.Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Reistone Biopharma Company Limited
• Sanofi
• Upstream Biosciences

Key Products

• Tezepelumab
• Depemokimab(GSK3511294)
• Solrikitug
• BBT002
• SPL5AC
• GSK3862995
• AZD6793
• GSK6582701/HRS-9821
• HSK39004
• Astegolimab
• TQC3721
• CM512
• CM310
• CM326
• RSS0343
• Lunsekimig
• Verekitug